{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:11:50Z","timestamp":1778803910882,"version":"3.51.4"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"5","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100021671","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021671","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","award":["HHSN261200800001E"],"award-info":[{"award-number":["HHSN261200800001E"]}],"id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","award":["HHSN2612015000031"],"award-info":[{"award-number":["HHSN2612015000031"]}],"id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","award":["75N910D00024"],"award-info":[{"award-number":["75N910D00024"]}],"id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite the efficacy of therapeutics and vaccines in reducing risk of severe coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections continue to occur and rebound symptoms after initial improvement have been well described. The mechanisms driving COVID-19 rebound remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Critical inflammatory responses were assessed by Imagestream, flow cytometry, and single-cell RNA sequencing in peripheral blood mononuclear cells from vaccinated individuals presenting with early (3 days postinfection, n = 6) or late (8 days postinfection, n = 6) acute symptoms, and clinical rebound (16 days postinfection, n = 8), as well as healthy volunteers (HV, n = 7).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>An overall decline in key inflammatory responses was observed in groups with longer time from symptom onset when compared to early acute infection. However, RNA sequencing revealed a partial resurgence of inflammatory, stress, and antiviral responses during clinical rebound, with a unique cluster of monocytes with greater activation of antigen presentation pathways and type I interferon signaling. Monocytes from patients with rebound COVID-19 also showed elevated inflammasome activation when compared to HV, along with an accumulation of oxidized lipids and decreased levels of glutathione, both hallmarks of the oxidative stress response. Inflammatory measurements positively associated with serum SARS-CoV-2 nucleocapsid antigen and inversely correlated with adaptive immune responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings potentially reflect viral reappearance posttreatment in participants with clinical rebound and outline mechanisms by which rebound symptoms are typically milder than during acute presentations. Extending the antiviral treatment period and\/or targeting inflammatory pathways could potentially prevent virological rebound or help mitigate associated symptoms.<\/jats:p>\n                    <jats:p>Clinical Trials Registration: NCT04401436.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiag037","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T12:46:20Z","timestamp":1768481180000},"page":"e1285-e1297","source":"Crossref","is-referenced-by-count":0,"title":["Inflammasome Activation and Oxidative Stress in SARS-CoV-2 Infection and Symptomatic Rebound"],"prefix":"10.1093","volume":"233","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8519-8164","authenticated-orcid":false,"given":"Silvia","family":"Lucena Lage","sequence":"first","affiliation":[{"name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4307-4934","authenticated-orcid":false,"given":"Joseph M","family":"Rocco","sequence":"additional","affiliation":[{"name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2860-3546","authenticated-orcid":false,"given":"Cihan","family":"Oguz","sequence":"additional","affiliation":[{"name":"Integrated Data Sciences Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-173X","authenticated-orcid":false,"given":"Francisco","family":"Otaizo-Carrasquero","sequence":"additional","affiliation":[{"name":"Research Technologies Branch, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Hamilton, Montana ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Rupert","sequence":"additional","affiliation":[{"name":"AIDS Monitoring Laboratory, Frederick National Laboratory for Cancer Research , Frederick, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin L","family":"Boswell","sequence":"additional","affiliation":[{"name":"Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7434-942X","authenticated-orcid":false,"given":"Brian P","family":"Epling","sequence":"additional","affiliation":[{"name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Logan","family":"Cook","sequence":"additional","affiliation":[{"name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Pinheiro Amaral","sequence":"additional","affiliation":[{"name":"Immunobiology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Laidlaw","sequence":"additional","affiliation":[{"name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances","family":"Galindo","sequence":"additional","affiliation":[{"name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A","family":"Koup","sequence":"additional","affiliation":[{"name":"Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5994-2727","authenticated-orcid":false,"given":"Princy","family":"Kumar","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Tropical Medicine, Georgetown University Medical Center , Washington District of Columbia ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Poon","sequence":"additional","affiliation":[{"name":"Division of Hospital Medicine, MedStar Georgetown University Hospital , Washington, District of Columbia ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn W","family":"Wortmann","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, MedStar Washington Hospital Center , Washington, District of Columbia ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1475-356X","authenticated-orcid":false,"given":"Andrea","family":"Lisco","sequence":"additional","affiliation":[{"name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0991-0011","authenticated-orcid":false,"given":"Maura","family":"Manion","sequence":"additional","affiliation":[{"name":"Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irini","family":"Sereti","sequence":"additional","affiliation":[{"name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"2026051419582693900_jiag037-B1","author":"World Health Organization"},{"key":"2026051419582693900_jiag037-B2","doi-asserted-by":"crossref","first-page":"e159474","DOI":"10.1172\/jci.insight.159474","article-title":"SARS-CoV-2-specific immune responses in boosted vaccine recipients with breakthrough infections during the Omicron variant surge","volume":"7","author":"Woldemeskel","year":"2022","journal-title":"JCI Insight"},{"key":"2026051419582693900_jiag037-B3","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"2026051419582693900_jiag037-B4","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe Covid-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N Engl J Med"},{"key":"2026051419582693900_jiag037-B5","doi-asserted-by":"crossref","first-page":"e537","DOI":"10.1093\/cid\/ciac481","article-title":"Rebound phenomenon after nirmatrelvir\/ritonavir treatment of coronavirus disease 2019 (COVID-19) in high-risk persons","volume":"76","author":"Ranganath","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026051419582693900_jiag037-B6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/cid\/ciad102","article-title":"The coronavirus disease 2019 rebound study: a prospective cohort study to evaluate viral and symptom rebound differences in participants treated with nirmatrelvir plus ritonavir versus untreated controls","volume":"77","author":"Pandit","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026051419582693900_jiag037-B7","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1473-3099(23)00063-4","article-title":"SARS-CoV-2 rebound with and without antivirals","volume":"23","author":"Petrosillo","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2026051419582693900_jiag037-B8","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.7326\/M23-1756","article-title":"SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy: an observational study","volume":"176","author":"Edelstein","year":"2023","journal-title":"Ann Intern Med"},{"key":"2026051419582693900_jiag037-B9","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.15585\/mmwr.mm7251a1","article-title":"SARS-CoV-2 rebound with and without use of COVID-19 oral antivirals","volume":"72","author":"Smith","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026051419582693900_jiag037-B10","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1093\/cid\/ciac512","article-title":"Characterization of virologic rebound following nirmatrelvir-ritonavir treatment for coronavirus disease 2019 (COVID-19)","volume":"76","author":"Boucau","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026051419582693900_jiag037-B11","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/cid\/ciac663","article-title":"Clinical, virologic, and immunologic evaluation of symptomatic coronavirus disease 2019 rebound following nirmatrelvir\/ritonavir treatment","volume":"76","author":"Epling","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026051419582693900_jiag037-B12","doi-asserted-by":"crossref","first-page":"799558","DOI":"10.3389\/fimmu.2021.799558","article-title":"Persistent oxidative stress and inflammasome activation in CD14(high)CD16(-) monocytes from COVID-19 patients","volume":"12","author":"Lage","year":"2022","journal-title":"Front Immunol"},{"key":"2026051419582693900_jiag037-B13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol Cell"},{"key":"2026051419582693900_jiag037-B14","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1083\/jcb.201602089","article-title":"The cell biology of inflammasomes: mechanisms of inflammasome activation and regulation","volume":"213","author":"Sharma","year":"2016","journal-title":"J Cell Biol"},{"key":"2026051419582693900_jiag037-B15","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.cell.2014.02.008","article-title":"Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes","volume":"156","author":"Lu","year":"2014","journal-title":"Cell"},{"key":"2026051419582693900_jiag037-B16","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.chom.2010.11.007","article-title":"Differential requirement for caspase-1 autoproteolysis in pathogen-induced cell death and cytokine processing","volume":"8","author":"Broz","year":"2010","journal-title":"Cell Host Microbe"},{"key":"2026051419582693900_jiag037-B17","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nature15514","article-title":"Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death","volume":"526","author":"Shi","year":"2015","journal-title":"Nature"},{"key":"2026051419582693900_jiag037-B18","doi-asserted-by":"crossref","first-page":"e20201707","DOI":"10.1084\/jem.20201707","article-title":"Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients","volume":"218","author":"Rodrigues","year":"2021","journal-title":"J Exp Med"},{"key":"2026051419582693900_jiag037-B19","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41586-022-04802-1","article-title":"Inflammasome activation in infected macrophages drives COVID-19 pathology","volume":"606","author":"Sefik","year":"2022","journal-title":"Nature"},{"key":"2026051419582693900_jiag037-B20","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/infdis\/jiad037","article-title":"CASP4\/11 contributes to NLRP3 activation and COVID-19 exacerbation","volume":"227","author":"Rodrigues","year":"2023","journal-title":"J Infect Dis"},{"key":"2026051419582693900_jiag037-B21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature10558","article-title":"Non-canonical inflammasome activation targets caspase-11","volume":"479","author":"Kayagaki","year":"2011","journal-title":"Nature"},{"key":"2026051419582693900_jiag037-B22","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41586-023-06742-w","article-title":"Recognition and maturation of IL-18 by caspase-4 noncanonical inflammasome","volume":"624","author":"Shi","year":"2023","journal-title":"Nature"},{"key":"2026051419582693900_jiag037-B23","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41586-022-04702-4","article-title":"FcgammaR-mediated SARS-CoV-2 infection of monocytes activates inflammation","volume":"606","author":"Junqueira","year":"2022","journal-title":"Nature"},{"key":"2026051419582693900_jiag037-B24","doi-asserted-by":"crossref","first-page":"e13372","DOI":"10.1111\/acel.13372","article-title":"Regulatory KIR+ RA+ T cells accumulate with age and are highly activated during viral respiratory disease","volume":"20","author":"Pieren","year":"2021","journal-title":"Aging Cell"},{"key":"2026051419582693900_jiag037-B25","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1126\/science.1217141","article-title":"GBP5 promotes NLRP3 inflammasome assembly and immunity in mammals","volume":"336","author":"Shenoy","year":"2012","journal-title":"Science"},{"key":"2026051419582693900_jiag037-B26","doi-asserted-by":"crossref","first-page":"eadq1086","DOI":"10.1126\/scitranslmed.adq1086","article-title":"Prior vaccination prevents overactivation of innate immune responses during COVID-19 breakthrough infection","volume":"17","author":"Chan","year":"2025","journal-title":"Sci Transl Med"},{"key":"2026051419582693900_jiag037-B27","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/infdis\/jiad045","article-title":"Vaccination ameliorates cellular inflammatory responses in SARS-CoV-2 breakthrough infections","volume":"228","author":"Huapaya","year":"2023","journal-title":"J Infect Dis"},{"key":"2026051419582693900_jiag037-B28","doi-asserted-by":"crossref","first-page":"5478","DOI":"10.1038\/s41467-024-49458-9","article-title":"A unifying model to explain frequent SARS-CoV-2 rebound after nirmatrelvir treatment and limited prophylactic efficacy","volume":"15","author":"Esmaeili","year":"2024","journal-title":"Nat Commun"},{"key":"2026051419582693900_jiag037-B29","doi-asserted-by":"crossref","first-page":"e0162324","DOI":"10.1128\/jvi.01623-24","article-title":"Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance","volume":"99","author":"Phan","year":"2025","journal-title":"J Virol"},{"key":"2026051419582693900_jiag037-B30","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S1473-3099(25)00221-X","article-title":"Extended nirmatrelvir-ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial","volume":"25","author":"Weinstein","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026051419582693900_jiag037-B31","doi-asserted-by":"publisher","author":"Deo","DOI":"10.1101\/2022.08.01.22278278"},{"key":"2026051419582693900_jiag037-B32","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41590-021-00869-6","article-title":"Inflammasomes and adaptive immune responses","volume":"22","author":"Deets","year":"2021","journal-title":"Nat Immunol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag037\/66477141\/jiag037.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/5\/e1285\/66477141\/jiag037.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/5\/e1285\/66477141\/jiag037.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:58:39Z","timestamp":1778803119000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/233\/5\/e1285\/8431589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,1,20]]},"published-print":{"date-parts":[[2026,5,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiag037","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,15]]},"published":{"date-parts":[[2026,1,20]]}}}